NCT06390722View on ClinicalTrials.gov

A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic Dermatitis

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 23, 2024

Primary Completion Date

January 5, 2026

Study Completion Date

July 8, 2026

Conditions
Atopic DermatitisSleep Disturbance
Interventions
DRUG

Upadacitinib

Oral Tablet

DRUG

Placebo for Upadacitinib

Oral Tablet

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY